Skip to main content
Equibles

CSCIF · COSCIENS Biopharma Inc. · Metrics

Track CSCIF — free

Use CSCIF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSCIF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.44 +0.02 (+0.31%) At close · Oct 2
Rebalance outlook locked
Market Cap
$6.63M
Shares
996,166
Volume · Oct 2 116 Avg daily vol (3M) 1259

CSCIF metrics

59 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.44
Market cap
$6.63M

Price action

20 metrics
Price change (1W)
+5.6%
Price change (30D)
+17.1%
Price change (3M)
+162.9%
Price change (6M)
+272.3%
Price change (YTD)
+212.6%
Price change (1Y)
+146.7%
Trailing year
Price change (5Y)
—
52-week high
$7.00
52-week low
$0.79
Change from 52-week high
-8.0%
Change from 52-week low
+715.2%
Annualized volatility
259.9%
Annualized volatility (3M)
—
Beta
-0.7
RSI (14D)
63.9
Price vs SMA 50
+34.7%
Price vs SMA 200
+134.6%
Avg volume (3M)
1,259
Relative volume
0.1
Average dollar volume
$7,082

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
996,166

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.9×
reciprocal yield 113.0%
P / book
1.7
reciprocal yield 57.9%
FCF yield
-138.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-156.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
35.3%
Operating margin
-142.5%
Trailing 12 months
Net margin
-138.1%
Gross profit (TTM)
$2.65M
Operating profit (TTM)
−$10.68M
Net income (TTM)
−$10.36M
Trailing 12 months
Diluted EPS (TTM)
$-3.27
FCF margin
-122.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.21

Growth

11 metrics
Revenue growth YoY
-46.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.50M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
-19.9%
Revenue CAGR (5Y)
+15.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-269.6%
Return on assets
-48.3%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
−$10.01M
Free cash flow (TTM)
−$9.18M
Quick ratio
2.8
Interest coverage
-63.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.31M
Total assets
$21.43M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.47M
Capital expenditures (TTM)
$706,000
R&D (TTM)
$2.95M
SG&A (TTM)
—
Stock compensation (TTM)
−$12,000
R&D / revenue
39.3%
Stock compensation / revenue
-0.2%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 12.7 days to cover
Days to cover
12.7d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1113423 CUSIP 22112H200 Visit website Investor relations